Werida et al. demonstrated that, in patients with T2D and dyslipidemia, rosuvastatin 10 mg produced significantly greater reductions in HbA1c, LDL-C, triglycerides, total cholesterol, atherogenic index, and inflammatory markers, including high-sensitivity C-reactive protein, sortilin, leptin, and adiponectin compared with atorvastatin 20 mg [22]. This evidence concerns the gene LEP and metabolic syndrome.